Addex Spin-Out Neurosterix Wraps Phase 1 Of NTX-253 With Single And Multiple Ascending Dose Studies Providing Safety And Pharmacokinetic Data, Plans Phase 2 Schizophrenia Development
Share
Why It Matters
Neurosterix finished early testing of a new schizophrenia medicine. The drug was safe, so the company plans larger human tests next.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.